Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients

NCT01908712 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Alpha-Mannosidosis

Interventions

DRUG: Lamazym

Sponsor

Chiesi Farmaceutici S.p.A.